Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
तुलना करने के लिए मीट्रिक्स | PALI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPALIपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −20.3x | −3.4x | −0.4x | |
PEG अनुपात | −0.21 | −0.10 | 0.00 | |
क़ीमत/बुक | 2.6x | 4.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 69.2x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 244.8% | 42.7% | 49.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 2.2% | 6.8% | अनलॉक करें |